Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M, Koh Y, Das D, Li J, Leschenko S, Wang YF, Boross PI, Weber IT, Ghosh AK, Mitsuya H. Amano M, et al. Among authors: koh y. Antimicrob Agents Chemother. 2007 Jun;51(6):2143-55. doi: 10.1128/AAC.01413-06. Epub 2007 Mar 19. Antimicrob Agents Chemother. 2007. PMID: 17371811 Free PMC article.
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H. Koh Y, et al. Antimicrob Agents Chemother. 2009 Mar;53(3):997-1006. doi: 10.1128/AAC.00689-08. Epub 2008 Oct 27. Antimicrob Agents Chemother. 2009. PMID: 18955518 Free PMC article.
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H. Aoki M, et al. Among authors: koh y. J Virol. 2009 Apr;83(7):3059-68. doi: 10.1128/JVI.02539-08. Epub 2009 Jan 28. J Virol. 2009. PMID: 19176623 Free PMC article.
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Tojo Y, Koh Y, Amano M, Aoki M, Das D, Kulkarni S, Anderson DD, Ghosh AK, Mitsuya H. Tojo Y, et al. Among authors: koh y. Antimicrob Agents Chemother. 2010 Aug;54(8):3460-70. doi: 10.1128/AAC.01766-09. Epub 2010 May 3. Antimicrob Agents Chemother. 2010. PMID: 20439612 Free PMC article.
Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H. Ide K, et al. Among authors: koh y. Antimicrob Agents Chemother. 2011 Apr;55(4):1717-27. doi: 10.1128/AAC.01540-10. Epub 2011 Jan 31. Antimicrob Agents Chemother. 2011. PMID: 21282450 Free PMC article.
3,245 results